Biomarkers for T-DXd Response

Trastuzumab deruxtecan (T-DXd), an anti-HER2-drug conjugate of the third generation, is used to treat HER2-positive metastatic breast cancer (mBC). Despite the fact that T-DXd offers some therapeutic advantages to patients with HER2-positive mBC, the majority of them eventually suffer from disease progression and pass away as a result of resistance to treatment.

The mode of action of T-DXd and the mechanisms of resistance are still unknown. Predicting the response to a treatment is challenging, but is of great importance for patients especially those suffering metastasis. The ability of modern biomarker analysis techniques to adapt to local population features and use current biological information is limited. Finding biomarkers and creating a knowledge-based machine learning framework that combines gene expression data with accepted biological information to forecast treatment response are the main objectives of our research.

We anticipate that the potential biomarkers will play important roles in detecting early response to T-DXd treatment. Should these biomarkers be observed, more in-depth experimental evidence is needed to ascertain whether the signature biomarkers would be regarded as viable diagnostic instruments for the therapeutic result and have potential for clinical use as biomarkers for HER2+ mBC patients to forecast the effectiveness of T-DXd.

Abdelilah Aboussekhra, Taher Twegiery, Saleh Najjar.